XtalPi Update: Profitability Confirmed, Revenue Up 403.8%

XtalPi Holdings Limited announced a strong financial performance for the six months ended June 30, 2025, with revenue surging 403.8% year-on-year to RMB517.1m, up from RMB102.6m in the prior year period. This growth was primarily fueled by its drug discovery solutions, which saw revenue increase by 615.2% to RMB435.2m, largely due to a major collaboration with DoveTree Medicines LLC and significant antibody business growth. Intelligent robotics solutions also contributed to the strong results, with revenue rising 95.9% to RMB81.9m.

The company achieved profitability for the first time on a half-year basis, reporting an adjusted net profit of RMB141.6m, a substantial improvement from an adjusted net loss of RMB251.3m in 2024. This was coupled with a reduction in average monthly cash burn by 20.0% to RMB49.7m. As of June 30, 2025, XtalPi’s cash balance stood at RMB5,307.7m, providing approximately 107 months of financial viability based on current burn rates.

Operating profit for the period turned positive at RMB32.7m, compared to an operating loss of RMB392.9m in the previous year. The company's general and administrative expenses decreased by 14.5% to RMB200.3m, while research and development expenses saw a modest increase of 5.3% to RMB221.5m.